THC/CBD for Severe Dementia Behavioral Symptoms: A Two-Year Safety Pilot

Prospective observational study following 19 patients with severe dementia in a Swiss long-term care home. Patients received physician-prescribed THC/CBD treatment as an add-on to existing medications. Data collected over two years included cannabis dosages, safety parameters, neuropsychiatric inventory scores, agitation ratings, rigidity assessments, and pharmacokinetic measurements (plasma cannabinoid levels and enzyme activity).

Behavioral symptoms in dementia affect up to 90% of patients and are a primary reason for institutionalization and caregiver burnout. Current pharmacological options (mainly antipsychotics) carry FDA black box warnings for increased mortality in elderly dementia patients. If cannabinoids can safely reduce behavioral symptoms, they could offer a better risk-benefit profile — but this needs to be proven in controlled trials. This pilot provides the safety data needed to justify those larger studies.

This study sits alongside RTHC-00080 (cannabinoids for Parkinson's and dementia in older adults), building the case that cannabinoids may have a role in managing neurodegenerative disease symptoms in elderly patients. The drug interaction monitoring in this study also connects to the broader pharmacokinetic work in RTHC-00091 (CYP450 cannabinoid-drug interactions) — critical for a population taking multiple medications.

No control group — the biggest limitation. Without randomization and placebo comparison, improvements could reflect natural symptom fluctuation, placebo effects, or increased caregiver attention. Very small sample (19 patients) from a single facility. The patient population was predominantly female (17/19), limiting generalizability. Two-year retention data may reflect survivorship bias in this elderly, severely ill population.